Cancel anytime
Cidara Therapeutics Inc (CDTX)CDTX
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/08/2024: CDTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: -50.29% | Upturn Advisory Performance 2 | Avg. Invested days: 23 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 11/08/2024 |
Type: Stock | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: -50.29% | Avg. Invested days: 23 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 11/08/2024 | Upturn Advisory Performance 2 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 95.02M USD |
Price to earnings Ratio - | 1Y Target Price 57.25 |
Dividends yield (FY) - | Basic EPS (TTM) -24.6 |
Volume (30-day avg) 19066 | Beta 0.99 |
52 Weeks Range 10.00 - 24.40 | Updated Date 11/10/2024 |
Company Size Small-Cap Stock | Market Capitalization 95.02M USD | Price to earnings Ratio - | 1Y Target Price 57.25 |
Dividends yield (FY) - | Basic EPS (TTM) -24.6 | Volume (30-day avg) 19066 | Beta 0.99 |
52 Weeks Range 10.00 - 24.40 | Updated Date 11/10/2024 |
Earnings Date
Report Date 2024-10-31 | When BeforeMarket |
Estimate - | Actual - |
Report Date 2024-10-31 | When BeforeMarket | Estimate - | Actual - |
Profitability
Profit Margin -211.35% | Operating Margin (TTM) -3675.83% |
Management Effectiveness
Return on Assets (TTM) -15.66% | Return on Equity (TTM) -153.39% |
Valuation
Trailing PE - | Forward PE 5.75 |
Enterprise Value -65052747 | Price to Sales(TTM) 1.76 |
Enterprise Value to Revenue 0.61 | Enterprise Value to EBITDA -1.64 |
Shares Outstanding 7038240 | Shares Floating 4214006 |
Percent Insiders 4.73 | Percent Institutions 51.86 |
Trailing PE - | Forward PE 5.75 | Enterprise Value -65052747 | Price to Sales(TTM) 1.76 |
Enterprise Value to Revenue 0.61 | Enterprise Value to EBITDA -1.64 | Shares Outstanding 7038240 | Shares Floating 4214006 |
Percent Insiders 4.73 | Percent Institutions 51.86 |
Analyst Ratings
Rating 4.33 | Target Price 5.6 | Buy 2 |
Strong Buy 1 | Hold - | Sell - |
Strong Sell - |
Rating 4.33 | Target Price 5.6 | Buy 2 | Strong Buy 1 |
Hold - | Sell - | Strong Sell - |
AI Summarization
Cidara Therapeutics Inc.: A Comprehensive Analysis
Company Profile:
History and Background: Cidara Therapeutics Inc. (CDTX) is a clinical-stage biotechnology company founded in 2014 and headquartered in San Diego, California. It focuses on developing novel treatments for severe and life-threatening fungal and viral infections. Cidara's pipeline includes several promising therapies, including rezafungin for invasive candidiasis and echinocandin-based antifungal platform targeting serious fungal infections in hospitalized patients.
Core Business Areas: Cidara's primary focus is on:
- Antibacterial Resistance: Developing novel therapies to combat drug-resistant bacterial infections, with a lead candidate in Phase 3 development for prosthetic joint infections.
- Antiviral Therapies: Investigating potential treatments for viral infections, including respiratory syncytial virus (RSV).
- Proprietary Delivery Platform: Utilizing a proprietary platform for targeted delivery of therapeutic agents to improve efficacy and safety.
Leadership Team and Corporate Structure: Cidara's leadership team comprises experienced individuals with expertise in biotechnology and pharmaceutical development. The company has a Board of Directors and an Executive Leadership team responsible for driving strategy and growth.
Top Products and Market Share:
Top Products:
- Rezafungin, a novel echinocandin antifungal for invasive candidiasis
- CD101, a broad-spectrum antibacterial agent for prosthetic joint infections
- CD104, a novel RSV therapy targeting pediatric and adult populations
Market Share: Cidara's current products are still in development and not yet commercially available. Therefore, market share data is not yet available. However, the target markets for these therapies are substantial, with invasive candidiasis affecting over 300,000 patients and prosthetic joint infections impacting over 1 million patients annually.
Competitive Landscape: Cidara faces competition from several established pharmaceutical companies in the antifungal and antibacterial therapy markets. Key competitors include:
- Pfizer (PFE) with Vfend and Diflucan for antifungal treatments
- Merck (MRK) with Cancidas for antifungal treatments
- Roche (RHHBY) with Actemra and Rituxan for bacterial infections
Total Addressable Market: The global market for antifungal therapies is estimated at over $10 billion, while the market for antibiotic treatments exceeds $40 billion. These markets are expected to grow in the coming years due to increasing antibiotic resistance and evolving healthcare needs.
Financial Performance:
Financial Highlights:
- Revenue: Cidara currently has no product sales as it is in the clinical development stage.
- Net Income: The company has consistently reported net losses due to research and development expenses.
- Profit Margins: Cidara's profit margins are currently negative due to its pre-commercial stage.
- Earnings Per Share (EPS): No EPS is available as the company has not yet reported any profits.
Financial Health: Cidara's financial health is primarily dependent on its ability to secure funding for ongoing clinical trials and commercialization efforts. As of June 30, 2023, the company had approximately $154.4 million in cash and equivalents, which is estimated to fund its operations for the next 12 months.
Dividends and Shareholder Returns:
Dividend History: As a development-stage company, Cidara does not currently pay dividends.
Shareholder Returns: Cidara's stock price has recently experienced volatility due to market conditions and clinical trial results. Over the past year, the share price has declined significantly.
Growth Trajectory:
Historical Growth: Cidara has experienced rapid growth in recent years, driven by advancements in its clinical pipeline. The company successfully completed Phase 3 trials for its lead antifungal candidate, rezafungin, and is preparing for potential FDA submission.
Future Growth: Cidara has significant growth potential due to its promising pipeline and extensive research partnerships. The company's success will depend on the successful commercialization of its lead therapies and expansion into new areas, such as antiviral treatments.
Recent Initiatives: Cidara recently announced partnerships with leading pharmaceutical companies for co-development and commercialization opportunities, indicating its strategic direction towards market expansion.
Market Dynamics:
Industry Trends: The antimicrobial and antiviral therapy markets are experiencing significant growth driven by several factors, including increasing antibiotic resistance, evolving healthcare needs, and a growing elderly population. Advances in biotechnology and targeted drug development are also shaping the landscape.
Competitive Positioning: Cidara is well-positioned within the industry with its novel antifungal and antibacterial therapies targeting unmet medical needs. The company's proprietary delivery platform provides a competitive advantage for potential improved efficacy and safety profiles.
Competitors:
Key Competitors:
- Pfizer (PFE)
- Merck (MRK)
- Roche (RHHBY)
- Gilead Sciences (GILD)
- AbbVie (ABBV)
Market Share and Competitive Advantages: Cidara currently holds no market share as its products are not yet commercially available. However, the company's unique and potentially best-in-class therapies, coupled with its proprietary platform, offer competitive advantages that could differentiate it from established players in the market.
Potential Challenges and Opportunities:
Key Challenges: Cidara faces various challenges, including potential setbacks in clinical development, regulatory approvals, market competition, and securing future funding.
Opportunities: The company has several opportunities for growth, such as expanding its pipeline with new therapies, securing strategic partnerships, and exploring new market segments. Additionally, the increasing demand for antimicrobialtherapies and potential regulatory approvals could lead to significant market opportunities.
Recent Acquisitions:
Cidara has not made any acquisitions in the past 3 years.
AI-Based Fundamental Rating:
Overall Rating: Based on an AI-driven analysis of Cidara's financials, technical indicators, market positioning, and competitive landscape, the current stock rating is 5 out of 10.
Justification: Cidara has a promising pipeline and significant growth potential, with its lead antifungal candidate on the verge of potential FDA approval. However, the company's pre-commercial stage, lack of product revenue, and current financial losses present substantial risk factors. Additionally, the competitive landscape is fierce, and market success is contingent on product approval and commercialization execution.
Sources and Disclaimers:
Sources: This analysis utilized information from Cidara Therapeutics Inc.'s official website, SEC filings, news articles, and market research reports.
Disclaimer: The information provided herein is for informational purposes only and should not be construed as financial advice. Please consult with a qualified financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cidara Therapeutics Inc
Exchange | NASDAQ | Headquaters | San Diego, CA, United States |
IPO Launch date | 2015-04-15 | President, CEO & Executive Director | Dr. Jeffrey L. Stein Ph.D. |
Sector | Healthcare | Website | https://www.cidara.com |
Industry | Biotechnology | Full time employees | 69 |
Headquaters | San Diego, CA, United States | ||
President, CEO & Executive Director | Dr. Jeffrey L. Stein Ph.D. | ||
Website | https://www.cidara.com | ||
Website | https://www.cidara.com | ||
Full time employees | 69 |
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.